Science: WHO raises global strength to find COVID-19 special effects!

On Friday, the WHO announced a large-scale global trial called SOLIDARITY to help fuel drug development by involving thousands of patients in dozens of countries in the development of special-effects drugs through a standardized, simple experimental design that could quickly gather strong scientific data during a pandemic:10.1126/science.abb8497Specifically, when a patient diagnosed with COVID-19 is considered eligible for the trial, the doctor may enter its data, including the underlying disease, into the WHO website, and the participant must sign an informed consent form, scan it and send it electronically to the WHOAfter the doctor explains the drugs available in the hospital, the website randomly matches a local standard care for the available drug or COVID-19During this time, the doctor will record the date of the patient's departure or death, the length of his stay, and whether the patient needs oxygen or ventilationunlike previous experiments, the study no longer follows the gold standard of medical research, "double blindness." Therefore, if the patient knows that they have received a candidate drug, it may have a comforting effectAna Maria Henao-Restrepo, medical officer at WHO's Department of Immunization, Vaccines and Biologicalproducts, said she hopes to set up a support document ation and data management center next week, "and we're doing that in record time."an obvious benefit of this study is that the design is simpler and more consistent, making it easier for hospitals under great pressure to participate"No one wants to increase the burden on front-line health care workers who are already overwhelmed and risking their lives," said Arthur Caplan, a bioethicist at NYU Langone Medical Centerthe list of drugs was compiled by a team of researchers for the World Health Organization, who have been evaluating information on candidate therapies since January and have selected the four safest and most likely drugs in clinical trialsIf the trials show that they work, there is likely to be enough drug supply to treat large numbers of patientstwo days after the WHO announced the SOLIDARITY experiment, France's National Institute of Medical Research announced that it would coordinate an additional trial in Europe called DiscoveryThe trial will follow the WHO example of testing 3,200 patients in seven countries, including France, Spain and the United Kingdom, on three drugs other than chloroquineHenao-Restrepo said rigorous clinical studies during outbreaks were always a challenge, but "it's important to get answers as quickly as possible and find effective and ineffective methods." We believe that random evidence is the best way to do thishere's the drug solidarityy will be tested:1Remcywe
originally developed by Gilead to fight the Ebola virus It can shut down viral replication by inhibiting a key viral enzyme RNA-dependent RNA polymerase Although the drug did not show any effect in trials treating Ebola, the first U.S COVID-19 treatment process, published in January by NEJM, revealed remxib's potential in treating COVID-19 2 chloroquine and hydroxychloroquine Although the two drugs were called "rule changers" by U.S President Donald Trump, they were not included in the testing until March 13, when the World Health Organization realized at a meeting that the drug had received "significant attention" in many countries Both drugs work by reducing the acidity of the internal body Studies have shown that these two drugs can effectively reduce the viral load in the nasal swabs of COVID-19 patients, but more reliable data are needed to prove their efficacy and effects on the human body 3 Creech (Litonavir/Lopinavir) In 2000, the drug combination Creech of Litonavir/Lopinavir was approved in the United States for the treatment of HIV infection Subsequent studies have shown that Cresser can not only be used to inhibit THE protease of HIV, but also to inhibit proteases of coronaviruses such as MERS and SARS However, a report by Chinese researchers published in NEMJ on March 15th showed that the combination of drugs did not show efficacy in clinical trials and could interact with drugs used by patients with severe illnesses, causing severe liver damage 4 Litonavir/Lopinavir and interferon beta interferon-beta is a molecule that regulates inflammation in the body In an experiment with MERS, the combination of Litonavir/Lopinavir and interferon beta showed better results in rhesus monkeys Currently, the combination of the three drugs is being conducted in the first randomized controlled trial in MERS patients in Saudi Arabia If this combination is to be used to treat COVID-19, Susanne Herold, a lung infection specialist at the University of Giessen in Germany, says it's best not to use it in seriously ill patients "If given at an advanced stage of the disease, it can easily lead to more serious tissue damage rather than helping patients " : [1] WHO launches global megatrial of the four most promising coronavirus treatments :Science:WHO,COVID-19!